Effect of Rimonabant on Glycemic Control in Insulin-Treated Type 2 Diabetes: The ARPEGGIO Trial

OBJECTIVE: To examine the efficacy and safety of rimonabant, a selective cannabinoid receptor type-1 antagonist, in patients with type 2 diabetes receiving insulin monotherapy. RESEARCH DESIGN AND METHODS: Patients (n = 368; A1C ≥7%) were randomized to 20 mg/day rimonabant or placebo in this 48-week...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Hollander, Priscilla A., Amod, Aslam, Litwak, León E., Chaudhari, Umesh
Médium: Artigo
Jazyk:Inglês
Vydáno: American Diabetes Association 2010
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2827517/
https://ncbi.nlm.nih.gov/pubmed/20009090
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc09-0455
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky